Danielle Victoriano, Class of 2019, Department of Ecology and Evolutionary Biology Telethon Kids Institute, Perth, Western Australia Funded by CHW under the Health Grand Challenge Program

Introduction

•Zostavax, used to prevent shingles

•November 2016, Zostavax became free for patient 70 to <80

•Lower efficacy in the age group, but higher incidence of disease

Objective of the Study

The aim of this study was to generate visualizations of the trends in administration, and most importantly, the safety of the vaccine in this particular age group.



Methods

• NPS data collected across 529 different general practices throughout Australia


•5 million patient records with 23,000 patients recorded for receiving Zostavax

•Used RStudio to generate graphs after a focus population was identified.

Results

- prior to and following day 0
- Encounter- a physician-patient interaction

Count of Encounters listed prior to and following Zoster Vaccination by Age




- conjunction with Zostavax
- could it be used with other vaccines
- no difference in


AusVaxSafety: **Descriptive Analysis for Zostavax**

A marker to determine safety of Zostavax was to compare number of patient-physician encounters

There is no change in the trend of visits after day




- Breaking it down by age was important because it would show if the vaccine is less safe at a certain age
- Lines for before and after Day 0 almost overlap, with small values of difference in the count value
- Majority of vaccinated are 70 or 79 year olds



Important to look at the trends here because it would show whether or not Zostavax would only be safe by itself or

Analysis of encounters prior to and following Day 0 show







Discussion

• The patients that are receiving Zostavax are the patients who constantly visit their doctors as can be seen with the spike every 7 days.

• The older the person, the more likely an increase in encounters because of vaccination as can be see by graph 2.

Questions

 What is the uptake like for patients that do not constantly go to their general practitioners?

•Do number of encounters increase after vaccination if a patient has a certain condition?

Conclusion

•Generally, based on these visualizations, Zostavax is a safe vaccine for patients 70 to <80, even if used in conjunction with the influenza vaccine.

Acknowledgements

I would like to thank Telethon Kids Institute, Perth for allowing me to conduct research this summer. I would like to recognize my supervisors, Dr. Tom Snelling and Dr. Julie Marsh for their guidance and support throughout this project. Last but not least, I would like to thank CHW and the Health Grand Challenge Program for sponsoring this opportunity.